Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Doah Cho"'
Autor:
Doah Cho, Sarah J. Lord, Robyn Ward, Maarten IJzerman, Andrew Mitchell, David M. Thomas, Saskia Cheyne, Andrew Martin, Rachael L. Morton, John Simes, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized controlled trials (RCTs) are often impractical in rare diseases, leading to calls for s
Externí odkaz:
https://doaj.org/article/01054442bb48485e8ed565d3f77224e0
Autor:
Doah Cho, Sarah J. Lord, John Simes, Wendy Cooper, Michael Friedlander, Susie Bae, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Next-generation sequencing is used to increase targeted treatment opportunities, particularly for patients who have exhausted standard options. Where randomized controlled trial evidence for a targeted therapy is available for molecular a
Externí odkaz:
https://doaj.org/article/7fa3741e3c5c428882709ca493e1fcd4
Publikováno v:
BMJ Open, Vol 12, Iss 7 (2022)
Objectives Cancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infea
Externí odkaz:
https://doaj.org/article/fb8e0d11adc14493985bdedd16769a0f
Publikováno v:
BMJ open. 12(7)
ObjectivesCancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infeas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737d9bd136f1d978e85bb8caa6566e50
https://pubmed.ncbi.nlm.nih.gov/35820758
https://pubmed.ncbi.nlm.nih.gov/35820758
Autor:
Saw Yee Yap, Vishal Boolell, Peter Savas, Robin Stuart-Harris, Alice R T Bergin, Stephen J Luen, Louise M. Nott, Lee Na Teo, Doah Cho, Jodi Lynch, Sherene Loi
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 15:377-382
Background Pertuzumab, when combined with trastuzumab and chemotherapy, is a highly active human epidermal growth factor receptor 2 (HER2), targeting agent in the neoadjuvant, adjuvant and first-line metastatic HER2-positive breast cancer setting. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f8cd6ac537164489b9a1b13584edf6
https://doi.org/10.1111/ajco.13195
https://doi.org/10.1111/ajco.13195
Publikováno v:
Cancer Research. 82:5963-5963
BACKGROUND: Advances in understanding of potentially targetable molecular pathways driving carcinogenesis coupled with rapid development of tumor profiling technologies are partitioning cancers into rare biomarker-defined diseases. Assessing biomarke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b788a8817ef24cc45b46bcaac13d96b
https://doi.org/10.1158/1538-7445.am2022-5963
https://doi.org/10.1158/1538-7445.am2022-5963
Autor:
Georgia Ritchie, Sarah J. Lord, John Simes, Won-Hee Yoon, Doah Cho, Ian C. Marschner, Peey-Sei Kok, Chee Khoon Lee, Michael Friedlander
Publikováno v:
JAMA Network Open
Key Points Question Can surrogate end points, such as progression-free survival, be used to estimate overall survival in immunotherapy trials? Findings This systematic review and meta-analysis using data from 60 published immunotherapy randomized cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186694ef81d90b00b62c5456ea327031
http://europepmc.org/articles/PMC7489825
http://europepmc.org/articles/PMC7489825
Autor:
John Simes, Sarah J. Lord, Felicia T. Roncolato, Johnathan Man, Doah Cho, Matthew Links, Chee Khoon Lee
Publikováno v:
JCO Precision Oncology. :1-12
Purpose The demand for more rapid access to novel biologic therapies than randomized controlled trials can deliver is a topic of ongoing study and debate. We aimed to inform this debate by estimating therapeutic success from phase III trials comparin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed3f914067491bf2ac73053a1711178
https://doi.org/10.1200/po.17.00062
https://doi.org/10.1200/po.17.00062
Autor:
Ian C. Marschner, Sarah J. Lord, Doah Cho, Chee Khoon Lee, Rebecca Asher, Jun Hee Hong, Kelli Snyders
Publikováno v:
Acta oncologica (Stockholm, Sweden). 59(1)
Background: Recent trials of novel agents in ‘rare’ molecular subtypes of non-small cell lung cancer (NSCLC) have used single-arm trial designs and benchmarked outcomes against historical controls....
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d7981986636e4870816612fd999bbe
https://pubmed.ncbi.nlm.nih.gov/31608733
https://pubmed.ncbi.nlm.nih.gov/31608733
Autor:
Doah Cho, Rahuram Sivasubramaniam, Tina Baillie, Chee Khoon Lee, Angelina Tjokrowidjaja, John Moses
Publikováno v:
Internal Medicine Journal. 47:1215-1216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::777095ee8eba1f1e670350f45861faa7
https://doi.org/10.1111/imj.13560
https://doi.org/10.1111/imj.13560